Skip to main content

Table 3 Efficacy outcomes of artemether–lumefantrine use during pregnancy

From: A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy

Publication Description Treatment (n) Fever clearance Parasite clearance Cure rate
McGready et al. , 2008[22] Thai study. Open- label, randomized study of AL vs. AS in the 2nd and 3rd trimesters AL (125) 2 (1–3) days 2 (1–5) days 87.2% (95% CI 81.1–93.2) at Day 42.82.0% (95% CI 74.8–89.3) at delivery (or Day 42 if later)
   AS (128) 1 (1–2) days 2 (1–5) days 95.2% (95% CI 91.5–97.1) at Day 42.89.2% (95% CI 82.3–96.1) at delivery (or Day 42 if later)
Kaye et al. , 2008[23] Ugandan study. Open-label, randomized study of AL vs. chlorproguanil-dapsone* in the 2nd and 3rd trimesters AL (58) 47 (85.5%) clear at Day 2 49 (89.1%) clear at Day 2 100% at Day 28
Piola et al., 2010[25] Ugandan study. Open-label, randomized study of AL vs. Q in the 2nd and 3rd trimesters AL (152) 130 (100%) clear at Day 2 148 (99%) clear at Day 2 99.3% (range 96.0–99.9)§ at Day 42.98.2% (range 93.5–99.7)§ at delivery (or Day 42 if later)
   Q (152) 127 (99%) clear at Day 2 123 (86%) clear at Day 2 97.6% (range 93.1–99.5)§ at Day 42.96.1% (range 90.2–98.9)§ at delivery (or Day 42 if later)
  1. AL artemether-lumefantrine; AS artesunate; CI confidence interval; Q quinine; *Chlorproguanil-dapsone has been withdrawn, so the chloroproguanil-dapsone data are not shown; median (range) days; PCR-adjusted, intent-to-treat population; §PCR-adjusted, modified intent-to-treat population.
\